Highmark Commercial Medical Policy - Pennsylvania |
Medical Policy: | G-46-001 |
Topic: | Inhaled Nitric Oxide |
Section: | Miscellaneous |
Effective Date: | August 27, 2018 |
Issue Date: | August 27, 2018 |
Last Reviewed: | June 2018 |
Inhaled nitric oxide (INO) is a natural vasodilator and has been studied for a variety of types of respiratory failure. Most commonly, it is used as an initial treatment for neonates with hypoxic respiratory failure to improve oxygenation and reduce the need for invasive extracorporeal membrane oxygenation. It is also proposed as a treatment for premature infants, critically ill children and adults with respiratory failure, as well as in the postoperative management of children undergoing repair of congenital heart disease and patients after lung transplantation to prevent or reduce reperfusion injury. |
This policy is designed to address medical guidelines that are appropriate for the majority of individuals with a particular disease, illness, or condition. Each person's unique clinical circumstances may warrant individual consideration, based on review of applicable medical records.
Policy Position Coverage is subject to the specific terms of the member’s benefit plan. |
Inhaled nitric oxide may be considered medically necessary as a component of treatment of hypoxic respiratory failure in neonates born at more than 34 weeks of gestation.
Inhaled nitric oxide is considered experimental/investigational, and therefore non-covered, because the safety and/or effectiveness cannot be established by available published peer-reviewed literature, including, but not limited to ANY ONE of the following indications:
Place of Service: Inpatient |
Experimental/Investigational (E/I) services are not covered regardless of place of service.
The policy position applies to all commercial lines of business |
Denial Statements |
Services that do not meet the criteria of this policy will be considered experimental/investigational (E/I). A network provider can bill the member for the experimental/investigational service. The provider must give advance written notice informing the member that the service has been deemed E/I. The member must be provided with an estimate of the cost and the member must agree in writing to assume financial responsibility in advance of receiving the service. The signed agreement must be maintained in the provider’s records.
Links |
06/2018, New Coverage Criteria Established for Inhaled Nitric Oxide